LM 004
Alternative Names: LM-004Latest Information Update: 30 Aug 2023
At a glance
- Originator LaNova Medicines Limited
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 30 Aug 2023 Preclinical trials in Solid tumours in China (Parenteral) (LaNova Medicines pipeline, August 2023)
- 04 Oct 2022 LM 004 is available for licensing as of 04 Oct 2022. https://www.lanovamedicines.com/foreign-cooperation?tp=2
- 04 Oct 2022 Preclinical trials in haematological-malignancies in China (Parenteral) (LaNova Medicines pipeline, October 2022)